Home › NDC Lookup › Ingredients › Erythromycin › 48102-0057-11
👁️image loading
(from DailyMed)

Erythromycin 5 mg/g Ointment, 50 tubes — NDC 48102-057-11 (Billing 48102-0057-11)

by Fera Pharmaceuticals, LLC · 50 TUBE in 1 CARTON / 1 g in 1 TUBE

This is a package of 50 tubes of Erythromycin 5 mg/g Ointment from Fera Pharmaceuticals, LLC, marketed since Sep 2023 and currently FDA-listed. It is this product's only package size.

NDC 48102-0057-11
🏷️ FDA NDC (as labeled) 48102-057-11 billing pads the product segment with a zero
Rx only On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 48102-057-11 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
48102 labeler · 057 product · 11 package
Package marketed since
Sep 27, 2023
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC)
0348102057110
FDA record last changed
Jul 24, 2026
⚠️
Other active recalls for Erythromycin (different manufacturers) — 2 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Apr 29, 2026 — CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit (Zydus Pharmaceuticals (USA) Inc) · FDA recall D-0545-2026
Class II · Apr 29, 2026 — CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit (Zydus Pharmaceuticals (USA) Inc) · FDA recall D-0544-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 48102-057-11
Product NDC 48102-057
11-digit billing NDC 48102005711
NCPDP billing unit GM — per gram (weight)
RxCUI 310149
UNII 63937KV33D
UPC 0348102057110
SPL Set ID be59bb85-8ef4-4f9e-85e5-c05662ecd1ee
Established class (EPC) Macrolide; Macrolide Antimicrobial
Physiologic effect Decreased Sebaceous Gland Activity
Chemical class Macrolides
DEA schedule Non-controlled
Marketing category UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2023-09-27
Route OPHTHALMIC
Dosage form OINTMENT
Substance ERYTHROMYCIN

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 007948
GCN 33540
HICL code 004022
Ingredient (HICL) Erythromycin Base
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q6
Therapeutic class — intermediate (HIC2) Ophthalmic Preparations
HIC3 code Q6W
Therapeutic class — specific (HIC3) Ophthalmic Antibiotics
AHFS code 08:12.12.04
AHFS class Erythromycin Antibiotics
FDB label name ERYTHROMYCIN 0.5% EYE OINTMENT
FDB brand name Erythromycin
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 007948
  • GCN: 33540
  • HICL (First Databank): 004022
  • AHFS class code: 08:12.12.04
  • RxCUI (RxNorm): 310149
Why two NDCs? The FDA registers this code as 48102-057-11 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 48102-0057-11. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Macrolide class.

Pharmacologic class Macrolide, Macrolide Antimicrobial
Drug family (ATC) Antiinfectives for treatment of acne, Macrolides, Antibiotics
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name ERYTHROMYCIN 0.5% EYE OINTMENT Ingredient Erythromycin Base
📗 Our plain-language guide HelloPharmacist
  • It’s an antibiotic for infections caused by susceptible bacteria. By mouth, it’s used for mild to moderate upper respiratory tract infections. The IV form covers additional infecti...
  • It depends on the product. Ery-tab delayed-release tablets can be taken with or without meals, but work best on an empty stomach. Erythromycin ethylsuccinate tablets and suspension...
  • Stomach upset is the most common. That includes nausea, vomiting, belly pain, diarrhea and loss of appetite. These tend to be more likely at higher doses. Call your doctor if they...
  • Call for severe or lasting diarrhea, hives or swelling, a severe skin rash, a racing or irregular heartbeat, fainting, yellow skin or eyes, or hearing changes. These can signal ser...
📖 Read our full Erythromycin guide →
7
Nutrient depletion considerations

Erythromycin may be associated with lower levels of 7 nutrients — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Erythromycin nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · Q2 2026 $3.24 $162.05 / 50 g
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
48102-0057-11 You're viewing this Main listing 50 TUBE in 1 CARTON / 1 g in 1 TUBE 2023-09-27 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Erythromycin 5 mg/g 24208-0910-19 Bausch 50 tubes $6.834 AT Availability likely —
Erythromycin 5 mg/g 70244-0031-01 Sentiss 50 tubes $6.834 AT Availability likely —
Erythromycin 5 mg/g 72485-0670-31 ARMAS 50 tubes $6.834 AT Availability likely —
Erythromycin 5 mg/gthis 48102-0057-11 Fera 50 tubes — — FDA listed —
Erythromycin 5 mg/g 50090-1484-00 A-S 1 tube — AT FDA listed —
erythromycin 5 mg/g 50090-1958-00 A-S 1 tube — — FDA listed —
Erythromycin 5 mg/g 55154-7850-00 Cardinal 10 tubes — AT FDA listed —
Erythromycin 5 mg/g 60760-0670-35 ST. 1 tube — AT FDA listed —
Erythromycin 5 mg/g 61919-0090-35 Direct 3.5 g — AT FDA listed —
Erythromycin 5 mg/g 63187-0267-35 Proficient 1 tube — AT FDA listed —
Erythromycin 5 mg/g 63187-0608-35 Proficient 1 tube — AT FDA listed —
Erythromycin 5 mg/g 66267-0975-35 NuCare 3.5 g — AT FDA listed —
Erythromycin 5 mg/g 67296-2128-03 Redpharm 1 tube — AT FDA listed —
Erythromycin 5 mg/g 68071-3992-02 NuCare 1 tube — AT FDA listed —
Erythromycin 5 mg/g 68071-4228-03 NuCare 3.5 g — AT FDA listed —
erythromycin 5 mg/g 68071-4803-03 NuCare 3.5 g — — FDA listed —
Erythromycin 5 mg/g 68788-9328-03 Preferred 1 tube — AT FDA listed —
Erythromycin 5 mg/g 70518-0465-00 REMEDYREPACK 1 tube — AT FDA listed —
Erythromycin 5 mg/g 76420-0196-03 Asclemed 1 tube — AT FDA listed —
Erythromycin 5 mg/g 76420-0212-30 Asclemed 1 tube — AT FDA listed —
erythromycin 5 mg/g 76420-0612-03 Asclemed 1 tube — — FDA listed —
Erythromycin 5 mg/g 85766-0248-55 Sportpharm 1 tube — AT FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2023
On the market since
Sep 2023
📍
2026
Currently FDA-listed
3 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Erythromycin inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII T5L8T28FGP
    Mineral oil is a clear, odorless liquid derived from crude oil. It acts as a lubricant and emollient in medications, helping pills slide smoothly during manufacturing and aiding moisture retention in topical products.
  • UNII 4T6H12BN9U
    Petrolatum is a purified mineral oil-based jelly derived from petroleum. In medicines, it acts as an emollient, lubricant, and moisture barrier to soften skin, reduce friction, and help prevent water loss from formulations.

2 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerFera Pharmaceuticals, LLC
Labeler code48102
First marketedSep 2023
Product typeHuman Prescription Drug
Portfolio3 products on file

More NDCs from Fera Pharmaceuticals, LLC labeler code 48102

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 Package Label / Principal Display Panel
📄 Package Label / Principal Display Panel 92 words ▾

Principal Display Panel - 5 mg Carton Label (Steri-Med) Sterile Sterile 50 x 1g unit dose tubes tubes unidose DIN 02326663 Pr ONGUENT OPHTALMIQUE D'ERYTHROMYCINE USP Pr ERYTHROMYCIN OPHTHALMIC OINTMENT USP 5 MG/G ANTIBIOTIC / ANTIBIOTIQUE Steri-Med Pharma Principal Display Panel - 5 mg Carton Label (Steri-Med)

Principal Display Panel - 5 mg Carton Label (Sterigen) STERILE/STERILE 50 x 1g unit dose tubes tubes unidose DIN 02326663 Pr Erythromycin Ophthalmic Ointment USP Pr Onguent Ophtalmique d'Erythromycine USP 5 mg/g ANTIBIOTIC / ANTIBIOTIQUE sterigen Principal Display Panel - 5 mg Carton Label (Sterigen)

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Erythromycin — the program that covers self-administered drugs. 12 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Erythromycin. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$6.84M
Claims incl. refills
399.1K
Beneficiaries
329.3K
Spend / beneficiary
$20.78
Spend / claim
$17.15
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Erythromycin — the ingredient across all brands.

Top reported reactions

Drug Hypersensitivity4,159
Nausea1,319
Vomiting1,157
Diarrhoea1,112
Dyspnoea1,076
Fatigue1,066
Rash1,046

Age at onset

Neonate107
Infant49
Child100
Adolescent64
Adult1,399
Elderly1,168

Reporter sex

19,105 reports
Male · 30%
Female · 70%
Unknown · 0%

Serious outcomes

Hospitalization5,067
Death1,712
Life-threatening1,327
Disabling1,168
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 1,844 379
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Finished prescription product Marketed without an FDA application

Listed without an FDA application

This product's marketing category indicates it is marketed without an approved FDA application (no NDA, ANDA, or BLA on file). Having an NDC does not by itself establish FDA approval — the NDC Directory is a listing system, not an approval decision. Approval-linked data such as Orange Book therapeutic-equivalence ratings therefore does not apply.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Unapproved Drug For Use In Drug Shortage". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Fera Pharmaceuticals, LLC. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Fera Pharmaceuticals, LLC is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 48102-0053-05 · Fera 48201-0001-12 · GRANDALL →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.